Beam Therapeutics

Beam Therapeutics operates as a biotechnology company. Through its subsidiaries, the company is a research stage biotechnology company committed to creating a new class of precision genetic medicines, based on the company's proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases.
  • TickerBEAM
  • ISINUS07373V1052
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
 PRESS RELEASE
BEAM Beam Therapeuti... (Health Care)

Beam Therapeutics to Participate in the 2021 William Blair Biotech Foc...

Beam Therapeutics to Participate in the 2021 William Blair Biotech Focus Conference CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the 2021 William Blair Biotech Focus Conference on Thursday, July 15, 2021 at 1:00 p.m. ET. The live webcast will be available in the investor section of the company's website at The webcast will be archived for 60 days following the presentation. A...

David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
 PRESS RELEASE
BEAM Beam Therapeuti... (Health Care)

Beam Therapeutics Announces Oral and Poster Presentations at 24th Amer...

Beam Therapeutics Announces Oral and Poster Presentations at 24th American Society of Gene and Cell Therapy Annual Meeting CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present data highlighting its proprietary base editing approach in several presentations during the 24th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, which will be hosted virtually May 11-14, 2021. In addition, Beam has been selected as a workshop presenter ...

David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
 PRESS RELEASE
BEAM Beam Therapeuti... (Health Care)

Beam Therapeutics Appoints Amy Simon, M.D., Chief Medical Officer

Beam Therapeutics Appoints Amy Simon, M.D., Chief Medical Officer CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that drug development expert Amy Simon, M.D., has been appointed as the company’s chief medical officer. Dr. Simon brings more than 20 years of clinical experience to Beam, serving in roles as a physician-scientist in academia and the biotechnology industry. “Amy is a dedicated physician and experienced drug developer who has worked across a wide range of...

 PRESS RELEASE
BEAM Beam Therapeuti... (Health Care)

Beam Therapeutics to Participate in the 2021 William Blair Biotech Foc...

Beam Therapeutics to Participate in the 2021 William Blair Biotech Focus Conference CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the 2021 William Blair Biotech Focus Conference on Thursday, July 15, 2021 at 1:00 p.m. ET. The live webcast will be available in the investor section of the company's website at The webcast will be archived for 60 days following the presentation. A...

 PRESS RELEASE
BEAM Beam Therapeuti... (Health Care)

Beam Therapeutics Announces Oral and Poster Presentations at 24th Amer...

Beam Therapeutics Announces Oral and Poster Presentations at 24th American Society of Gene and Cell Therapy Annual Meeting CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present data highlighting its proprietary base editing approach in several presentations during the 24th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, which will be hosted virtually May 11-14, 2021. In addition, Beam has been selected as a workshop presenter ...

 PRESS RELEASE
BEAM Beam Therapeuti... (Health Care)

Beam Therapeutics Appoints Amy Simon, M.D., Chief Medical Officer

Beam Therapeutics Appoints Amy Simon, M.D., Chief Medical Officer CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that drug development expert Amy Simon, M.D., has been appointed as the company’s chief medical officer. Dr. Simon brings more than 20 years of clinical experience to Beam, serving in roles as a physician-scientist in academia and the biotechnology industry. “Amy is a dedicated physician and experienced drug developer who has worked across a wide range of...

 PRESS RELEASE
BEAM Beam Therapeuti... (Health Care)

Beam Therapeutics Announces Acquisition of Guide Therapeutics

Beam Therapeutics Announces Acquisition of Guide Therapeutics GuideTx’s Proprietary LNP Screening Technology and Lipid Library Supports Expanded Targeting of Diverse Tissues for In Vivo Delivery of Gene Editing CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced it has completed the acquisition of Guide Therapeutics, Inc. (“GuideTx”), a developer of nonviral drug delivery vehicles for genetic medicines, further expanding the potential reach of Beam’s genetic medicines in...

 PRESS RELEASE
BEAM Beam Therapeuti... (Health Care)

Beam Therapeutics Inc. Announces $260 Million Common Stock Investment ...

Beam Therapeutics Inc. Announces $260 Million Common Stock Investment from Multiple Investors CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM) (the “Company”), a biotechnology company developing precision genetic medicines through base editing, today announced that it has agreed to sell 2,795,700 shares of its common stock to certain institutional investors in a private placement. The Company anticipates aggregate gross proceeds from the offering will be approximately $260 million, before deducting fees to the placement agents and other estimated o...

David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus

ResearchPool Subscriptions

Get the most out of your insights

Get in touch